The findings support the feasibility of clinical development for this series of compounds, with a proposed initial focus on CAPS patients to establish a clear proof-of-concept for NLRP3-mediated therapeutic effects. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.